Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic immunity seems to be a prerequisite for efficacy, as recently shown in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Escors, David, Bocanegra, Ana, Chocarro, Luisa, Blanco, Ester, Piñeiro-Hermida, Sergio, Garnica, Maider, Fernandez-Rubio, Leticia, Vera, Ruth, Arasanz, Hugo, Kochan, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655397/
https://www.ncbi.nlm.nih.gov/pubmed/36362027
http://dx.doi.org/10.3390/ijms232113241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655397/
https://www.ncbi.nlm.nih.gov/pubmed/36362027
http://dx.doi.org/10.3390/ijms232113241

Ejemplares similares